Skip to main content
SpringerLink
Log in

Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Owing to the special importance of the HER family in tumorigenesis, the downstream signaling pathways and effectors have become the key molecules in the strategy of carcinoma-targeted therapy. Recent evidence that HER3 is responsible for tumor resistance to therapeutic agents targeting EGFR or HER2/neu, along with the new findings that HER3 is involved in the process of dedifferentiation of gastric cancer (GC) have highlighted the critical role of HER3 in cancer research. HER3 is becoming a new targeted molecule in cancer treatment. Here, we comparatively investigated the expression of HER2/neu and HER3 in gastric cancer of two pathologic types (intestinal type and diffuse type) using immunohistochemistry (IHC) and analyzed the correlation between overexpression of HER2 and HER3 and clinicopathologic parameters.

Methods

An IHC study for HER2 and HER3 was performed on 102 formalin-fixed, paraffin-embedded specimens of GC—60 intestinal and 42 diffuse types. The correlation between overexpression of HER2 and HER3 and clinicopathologic parameters was statistically analyzed.

Results

In the GC group, overexpression of HER2 and HER3 was detected in 19 (18.6%) and 14 (13.7%) of 102 GC patients, respectively. In a nontumorous group of 102 specimens, 5 were HER2-positive (4.9%) (18.6% vs. 4.9%, p < 0.01), and 2 were HER3-positive (2.0%) (13.7% vs. 2.0%, p < 0.01). No co-overexpression of HER2 and HER3 was observed. The intestinal type of GC exhibited a higher rate of HER2 overexpression than did the diffuse type (26.7% vs. 7.1%, p < 0.05), whereas the diffuse type of GC exhibited a significantly higher rate of HER3 overexpression than did the intestinal type (26.2% vs. 5.0%, p < 0.01). The overexpression rates of HER2 and HER3 in phase III–IV (TNM stage) disease were significantly higher than that in phase I–II disease (24.0% vs. 7.7%, p < 0.05 and 22.0% vs. 5.8%, p < 0.05, respectively). HER2 and HER3 overexpression was also correlated with a significantly worse survival (p = 0.046 and 0.024, respectively).

Conclusions

The selective overexpression of HER2 and HER3 in the two histologic types of gastric cancer is strongly associated with a poor prognosis. Being an important member of the HER family, HER3 may become another candidate for molecular-targeted therapy in gastric cancer, especially for the diffuse histologic type.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bulanov D (2007) Gastric cancer-current state of the problem. Part I. Epidemiology, pathology, classification, staging. Khirurgiia (Sofiia) 4:48–59

    Google Scholar 

  2. Roder DM (2002) The epidemiology of gastric cancer. Gastric Cancer 5:5–11

    Article  PubMed  Google Scholar 

  3. Ahmed KM, Cao N, Li JJ (2006) HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res 26:4235–4243

    PubMed  CAS  Google Scholar 

  4. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485–498

    Article  PubMed  Google Scholar 

  5. Derin D, Eralp Y, Ozluk Y et al (2008) Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest 26:671–679

    Article  PubMed  CAS  Google Scholar 

  6. Burris H, Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13:289–298

    Article  PubMed  CAS  Google Scholar 

  7. Duneau JP, Vegh AP, Sturgis JN (2007) A dimerization hierarchy in the transmembrane domains of the HER receptor family. Biochemistry 46:2010–2019

    Article  PubMed  CAS  Google Scholar 

  8. Zaczek A, Brandt B, Bielawski KP (2005) The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 20:1005–1015

    PubMed  CAS  Google Scholar 

  9. Yokoyama H, Ikehara Y, Kodera Y et al (2006) Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 95:1504–1513

    Article  PubMed  CAS  Google Scholar 

  10. Pratilas CA, Hanrahan AJ, Halilovic E et al (2008) Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375–9383

    Article  PubMed  CAS  Google Scholar 

  11. Lesma E, Grande V, Ancona S et al (2008) Anti-EGFR antibody efficiently and specifically inhibits human TSC2/ smooth muscle cell proliferation: possible treatment options for TSC and LAM. PLoS ONE 3:e3558

    Article  PubMed  Google Scholar 

  12. Hirata A, Hosoi F, Miyagawa M et al (2005) HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65:4253–4260

    Article  PubMed  CAS  Google Scholar 

  13. Graeff P, Crijns AP, Ten Hoor KA et al (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99:341–349

    Article  PubMed  Google Scholar 

  14. Rusnak DW, Lackey K, Affleck K et al (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85–94

    PubMed  CAS  Google Scholar 

  15. Kim SY, Kim HP, Kim YJ et al (2008) Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32:89–95

    PubMed  Google Scholar 

  16. Inui T, Asakawa A, Morita Y et al (2006) HER-2overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. J Intern Med 260:484–487

    Article  PubMed  CAS  Google Scholar 

  17. Srinivasan R, Leverton KE, Sheldon H et al (2001) Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. Cell Signal 13:321–330

    Article  PubMed  CAS  Google Scholar 

  18. Kim KK, Lee JJ, Yang Y et al (2008) Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29:704–712

    Article  PubMed  CAS  Google Scholar 

  19. Akiyama T, Sudo C, Ogawara H (1986) The product of the human c-erbB–2 gene: a 185-kilo-dalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646

    Article  PubMed  CAS  Google Scholar 

  20. Sakai K, Mori S, Kawamoto T et al (1986) Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77:1047–1052

    PubMed  CAS  Google Scholar 

  21. Tokunaga A, Onda M, Okuda T et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer 75:1418–1425

    Article  PubMed  CAS  Google Scholar 

  22. Yano T, Doi T, Ohtsu A et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65–71

    PubMed  Google Scholar 

  23. Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15:413–448

    Article  PubMed  CAS  Google Scholar 

  24. Hayashi M, Inokuchi M, Takagi Y et al (2008) High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14:7843–7849

    Article  PubMed  CAS  Google Scholar 

  25. Katoh M, Yazaki Y, Sugimura T et al (1993) c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. Biochem Biophys Res Commun 192:1189–1197

    Article  PubMed  CAS  Google Scholar 

  26. Lordick F, Bang YJ, Kang YK (2007) HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer 5:271

    Google Scholar 

  27. Cooperative Study Group of HER2 in China (2006) Multicenter study on HER-2/new gene amplification and protein expression in patients with gastric cancer. Chin J Dig 26:657–660

    Google Scholar 

  28. Michimoto K, Akihiro I, Azusa SK et al (2003) Activation of ErbB3–PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene 22:1294–1301

    Article  Google Scholar 

  29. Sanidas EE, Filipe MI, Linehan J et al (1993) Expression of the c-erbB-3 gene product in gastric cancer. Int J Cancer 54:935–940

    Article  PubMed  CAS  Google Scholar 

  30. Yamashita K, Sakuramoto S, Kikuchi S et al (2008) Validation of staging systems for gastric cancer. Gastric Cancer 11:111–118

    Article  PubMed  Google Scholar 

  31. Tateishi M, Toda T, Minamisono Y et al (1992) Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol 49:209–212

    Article  CAS  Google Scholar 

  32. Sasano H, Date F, Imatani A et al (1993) Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24:584–589

    Article  PubMed  CAS  Google Scholar 

  33. Garcia I, Vizoso F, Martin A et al (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234–241

    Article  PubMed  CAS  Google Scholar 

  34. Okegawa T, Kinjo M, Nutahara K et al (2006) Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 13:1197–1201

    Article  PubMed  CAS  Google Scholar 

  35. Kapitanović S, Radosević S, Slade N et al (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126:205–211

    Article  PubMed  Google Scholar 

  36. Reschke M, Mihic-Probst D, van der Horst EH et al (2008) HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14:5188–5197

    Article  PubMed  CAS  Google Scholar 

  37. Lee HST, Crocker L, Yao E et al (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878–5887

    Article  Google Scholar 

  38. Narayan M, Wilken JA, Harris LN et al (2009) Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res 69:2191–2194

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China

    Xiu Li Zhang, Yun Sheng Yang, Ming Zhou Guo, Yan Gong & Jin Huang

  2. Laboratory of Gene Therapy, 302 Hospital of Chinese PLA, 100 Xisihuan Road, Beijing, 100039, China

    Dong Ping Xu & Jian Hui Qu

Authors
  1. Xiu Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun Sheng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong Ping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Hui Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming Zhou Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yun Sheng Yang.

Additional information

Xiu Li Zhang and Yun Sheng Yang equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, X.L., Yang, Y.S., Xu, D.P. et al. Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer. World J Surg 33, 2112–2118 (2009). https://doi.org/10.1007/s00268-009-0142-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-009-0142-z

Keywords

Search

Navigation